SCHEMBL3482655

SCHEMBL3482655

CCCC(C)OC(=O)/C=C/C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 8/20 0.59
ACHE P22303 1/20 0.36
BACE1 P56817 1/20 0.36
CHRM1 P11229 1/20 0.35
AKR1A1 P14550 1/20 0.35
CHRM3 P20309 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
ADRA1A P35348 1/20 0.35
HRH1 P35367 1/20 0.35
DRD3 P35462 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
ATM Q13315 1/20 0.35
TSHR P16473 2/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740812 1.00 HCAR2 (0.59) HCAR2ACHEBACE1CHRM1AKR1A1
SCHEMBL9328098 1.00 HCAR2 (0.59) HCAR2ACHEBACE1CHRM1AKR1A1
SCHEMBL4583113 0.92 HCAR2 (0.45) HCAR2CHRM1AKR1A1CHRM3HTR2A
SCHEMBL9328093 0.92 HCAR2 (0.45) HCAR2CHRM1AKR1A1CHRM3HTR2A
SCHEMBL4583109 0.92 HCAR2 (0.45) HCAR2CHRM1AKR1A1CHRM3HTR2A
SCHEMBL3482317 0.89 HCAR2 (0.55) HCAR2ACHEBACE1ALDH1A1ATM
SCHEMBL11407409 0.89 HCAR2 (0.55) HCAR2ACHEBACE1ALDH1A1ATM
SCHEMBL20563886 0.89 HCAR2 (0.46) HCAR2ACHEBACE1CHRM1AKR1A1
SCHEMBL3482324 0.89 HCAR2 (0.55) HCAR2ACHEBACE1ALDH1A1ATM
SCHEMBL7543926 0.86 HCAR2 (0.55) HCAR2CHRM1AKR1A1CHRM3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109044985-A Pharmaceutical preparation comprising one of corrosion skeleton or a variety of fumarates 前进制药知识产权有限公司 2018-12-21 CN claimed
CN-102369001-A Pharmaceutical formulation comprising one or more fumaric acid esters in an eroding matrix FORWARD PHARMA AS 2012-03-07 CN claimed
CN-102369000-A Pharmaceutical compositions comprising one or more fumaric acid esters FORWARD PHARMA AS 2012-03-07 CN claimed
WO-2024225302-A1 NOVEL FUMARIC ACID ESTER MONOMER, RESIN, AND FILM CONTAINING SAME 東ソー株式会社 2024-10-31 WO disclosed
CN-118355062-A Gas barrier film and packaging material DIC株式会社 2024-07-16 CN disclosed
EP-3603954-B1 POLYMER SUBSTRATE WITH HARD COAT LAYER TEIJIN LTD (JP) 2024-03-20 EP disclosed
US-11866564-B2 Polymer substrate with hard coat layer TEIJIN LIMITED (JP) 2024-01-09 US disclosed
EP-3575333-B1 ACTIVE-ENERGY-RAY-CURABLE AQUEOUS RESIN COMPOSITION AND UNDERCOAT AGENT FOR INORGANIC-MATERIAL THIN FILM DAINIPPON INK & CHEMICALS (JP) 2023-09-06 EP disclosed
EP-3486262-B1 ACTIVE-ENERGY-RAY-CURABLE RESIN COMPOSITION AND METAL-THIN-FILM UNDERCOAT AGENT DAINIPPON INK & CHEMICALS (JP) 2023-05-10 EP disclosed
US-11306172-B2 Active-energy-ray-curable resin composition and metal-thin-film undercoat agent DIC CORPORATION (JP) 2022-04-19 US disclosed
EP-3354455-B1 POLYMER SUBSTRATE WITH HARDCOAT LAYER, AND MANUFACTURING METHOD FOR SAME TEIJIN LTD (JP) 2022-02-09 EP disclosed
US-20150284556-A1 PHOTOPOLYMERIZABLE MOLDING RESIN COMPOSITION AND MOLDED MULTILAYER ARTICLE DIC CORPORATION (JP) 2015-10-08 US disclosed
US-8420764-B2 Compound having silsesquioxane skeleton and its polymer JNC CORPORATION (JP) 2013-04-16 US disclosed
US-20120178894-A1 COMPOUND HAVING SILSESQUIOXANE SKELETON AND ITS POLYMER INAGAKI JYUN-ICHI (JP) 2012-07-12 US disclosed
CN-102369001-A Pharmaceutical formulation comprising one or more fumaric acid esters in an eroding matrix FORWARD PHARMA AS 2012-03-07 CN disclosed
CN-102369000-A Pharmaceutical compositions comprising one or more fumaric acid esters FORWARD PHARMA AS 2012-03-07 CN disclosed
US-7705105-B2 A cyclic polymer of silsesquioxane skeleton with side chains formed byhydrosilation of an unsaturated end group containing an active polymerfunctional group; polyimidesiloxane copolymers; polyestersiloxane copolymers; high molecular weight; thin films; strength; heat resistance;waterproofing; CHISSO PETROCHEMICAL CORPORATION (JP) 2010-04-27 US disclosed
US-20070190344-A1 Verification of translation JNC CORPORATION (JP) 2007-08-16 US disclosed
US-20050009982-A1 Compound having silsesquioxane skeleton and its polymer CHISSO CORPORATION (JP) 2005-01-13 US disclosed
US-20040096757-A1 Photosensitive resin compositon, photosesitive resist for color filter, and process for producing color filter DAINIPPON INK AND CHEMICALS, INC. (JP) 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009982-A1 Compound having silsesquioxane skeleton and its polymer C1S, H1-4, H1-0 HCAR2 2928/4885ACHE 3372/4885BACE1 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.